$BIO

Bio-Rad Laboratories (NYSE: BIO, BIO.B) launched Foresight Pro chromatography columns packed with Nuvia resins for biomanufacturing. The columns, available in various sizes, are designed for downstream processing in drug development. According to the company, the single-lot packing approach ensures consistency and superior support for biopharma customers.

Bio-Rad Laboratories (BIO) shares rose 19.1% in the past month, driven by digital PCR demand and steady Clinical Diagnostics performance. However, Life Science demand remains weak, and the stock trades at a premium valuation. Management expects cost savings to support margins, but investors must weigh execution against subdued end markets. BIO's Digital PCR revenues grew 6% YoY, with instrument revenues up over 20%. Clinical Diagnostics sales were $399M, up 2.6% YoY. Life Science sales fell 4.1%

Danaher (DHR) reported Q2 2026 results with $6.3B revenue (+5.5% YoY), adj. EPS $1.94 (+8%), and raised full-year 2026 adj. EPS guidance to $8.45–$8.60, but its bioprocessing unit missed expectations. The move pressured Sartorius and Bio-Rad (BIO), which has a $5B strategic stake in Sartorius. Bio-Rad reported Q2 net sales $651M flat YoY and launched a restructuring with $80–$90M pre-tax charges.

South Korean biotech stocks rose as the KOSDAQ rebounded. FromBio surged to the daily upper limit after trading resumed following a 5-for-1 reverse stock split, closing at 3,330 won (+29.82%). It reported 72.2b won revenue in 2025 and an 18.6b won operating loss. Curacle jumped over 18% on hopes of follow-on licensing after its $1.08b MT-103 deal.

Bio-Rad Laboratories (BIO) said Q2 demand from academic and government customers stayed below historical levels, especially in the Americas, though NIH outlays are rising. It reported stabilization signs in biopharma, with China revenue down in the high teens and a ~$4M H2 headwind. Q2 non-GAAP EPS was $2.62. Gross margin was 53.1%. Bio-Rad reaffirmed 2026 guidance and announced restructuring with $30M-$35M annualized savings.

BIO-RAD LABORATORIES, INC. (BIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release Bio-Rad Reports Second -Quarter 2026 Financial Results HERCULES, Calif.—August 4, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for

Citigroup has lowered its rating on Bio-Rad Laboratories (BIO) to Neutral and reduced its price target from $375 to $300, citing concerns over the company's process chromatography segment and diagnostic operations in China. Despite this, Bio-Rad recently expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies, enhancing its capabilities in drug development and monitoring. The article suggests that while Bio-Rad has investment potential, other AI stocks may offer greater upside with less risk.

The company doesn't seem like it will generate pops in key fundamentals anytime soon.

Bio-Rad (BIO) delivered earnings and revenue surprises of -1.74% and +0.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.